Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Hypnotics Stories

2010-10-18 23:19:00

POINT RICHMOND, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced its preliminary analysis of data from the recently completed Intermezzo® 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study. Transcept is developing Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. In the...

2010-09-20 04:29:00

DALLAS, September 20, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Insomnia Market Forecast Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33201-insomnia-market-forecast.html Search More Then 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Datamonitor Research Reports at http://www.reportsandreports.com/Publishers/datamonitor/ The availability of...

2010-07-05 08:59:00

TEL AVIV, Israel, July 5, 2010 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.Neurim.com) confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over. The approval was based primarily on data obtained in the latest SOUNDER-SLEEP Phase IV clinical study, indicating that Circadin was safe and more effective...

2010-06-07 14:03:44

When seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity. In a paper published in the June Academic Emergency Medicine, UC emergency medicine assistant professor Jason McMullan, MD, found that the best means of stopping status epilepticus (SE) may be with the least direct medication. In the meta-analysis, McMullan compiled the results of six studies featuring 774 patients. His analysis...

2237edbbcbca7d3a21083dd293a43e1f1
2010-06-07 06:40:00

Individuals with chronic insomnia have an elevated risk of death, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC. Results indicate that the adjusted hazard ratio for all-cause mortality was three times higher in people with chronic insomnia (HR = 3.0) than in people without insomnia.  When examining individual subtypes of insomnia, the risk of...

2010-04-27 13:34:00

WASHINGTON, April 27 /PRNewswire-USNewswire/ -- AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration (FDA), the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team (HEAT) announced today. Such unapproved uses are also known as "off-label" uses because they...

2010-04-19 08:15:00

WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018. Phase IIb trial results show significant improvement in Hamilton Depression Rating Scale scores on the effect on...

2010-04-15 10:35:00

NORTH KINGSTOWN, R.I., April 15 /PRNewswire/ -- Unintentional poisoning deaths have dramatically increased over the last decade to become the second leading cause of injury deaths in the United States. Along with this trend, the number of Emergency Room visits and resulting hospitalizations has also increased. According to a recent study conducted by the West Virginia School of Medicine, hospitalizations for poisonings from overdoses of prescription opioids, sedatives and tranquilizers...

2010-03-17 14:00:00

MORRISTOWN, N.J., March 17 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately. "We're very pleased to add Alprazolam ODT to our portfolio and complete our Alprazolam family of offerings, which also includes Alprazolam extended-release and immediate release...

2010-03-10 15:00:00

FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review. "We are pleased that the lurasidone NDA has been accepted for...